Coherus BioSciences to Report Third Quarter Financial Results on November 5th
Coherus BioSciences, Inc. (Nasdaq: CHRS) will release its third quarter 2020 financial results on November 5, 2020, after market close. A conference call will follow at 4:30 p.m. EST to discuss the results and provide business updates. Investors can access the financial results on Coherus' website after the announcement. The company focuses on developing and commercializing biosimilars, including its product UDENYCA® and additional candidates like CHS-1420 and CHS-2020, targeting various chronic diseases.
- Coherus is positioned as a leader in the global biosimilar marketplace.
- The company has multiple product candidates in development, including CHS-1420 and CHS-2020.
- None.
REDWOOD CITY, Calif., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2020 financial results will be released after market close on Thursday, November 5, 2020. Starting at 4:30 p.m. EST, Coherus’ management team will host a conference call to discuss financial results and provide a general business update.
After releasing third quarter financial results, the Company will post them on the Coherus website at https://investors.coherus.com.
Conference Call Information
When: Thursday, November 5, 2020 starting at 4:30 p.m. EST
Webcast: https://investors.coherus.com
Dial-in: 844-452-6826 (Toll-Free U.S. and Canada) or 765-507-2587 (International)
Please dial-in 15 minutes early to ensure a timely connection to the call.
Conference ID: 7079429
About Coherus BioSciences, Inc.
Coherus is a leading biosimilar company that develops and commercializes its own high-quality therapeutics as well as those of others seeking capable access to the United States market. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus commercializes UDENYCA® (pegfilgrastim-cbqv) in the United States and is advancing additional product candidates including CHS-1420, a Humira® (adalimumab) biosimilar, Bioeq’s Lucentis® (ranibizumab) biosimilar, Innovent’s Avastin® (bevacizumab) biosimilar towards commercialization, as well as CHS-2020, an Eylea® (aflibercept) biosimilar. For additional information, please visit www.coherus.com.
Contact
David S. Arrington
Investor Relations & Corporate Affairs
Coherus BioSciences, Inc.
darrington@coherus.com
+1 (650) 395-0196
FAQ
When will Coherus BioSciences announce its Q3 2020 results?
How can I listen to the Coherus earnings call?
What products does Coherus BioSciences develop?
